Associate Professor Michael J. Campion, TruScreen Medical Advisory Committee member, sits down to discuss the science behind TruScreen's Cervical Cancer Screening Device, it's clinical validation…
• TruScreen device roll-out continues after COVID-19 restrictions lifted • Four new hospitals added in Shanghai and Sichuan Province April 2020 • Distributor wins tender…
Cervical cancer technology company, TruScreen Limited (NZAX:TRU), advises that it wishes to provide to shareholders a copy of its latest investor presentation.
Eligible shareholders and Wholesale investors will receive their personalised application forms to apply for up to a maximum of NZ$50,000 of new shares, at $0.05…
